Anastrozole
| Evidence Level: L5 | Predicted Indications: 5 |
Table of Contents
Anastrozole: aromatase inhibitor → neuroblastoma
One-Sentence Summary
Anastrozole is an aromatase inhibitor that lowers oestrogen production. The TxGNN model predicts it may be relevant to neuroblastoma, with a score of 0.9953. No clinical trials or publications currently study this direction, so the prediction rests on the model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | neuroblastoma |
| TxGNN Prediction Score | 0.9953 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data |
| Number of Listed Products | at least 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Anastrozole is known as an aromatase inhibitor, a class that blocks the conversion of androgens to oestrogens. Whether this action has any bearing on neuroblastoma is not established.
The data compiled for this report found no established rationale linking aromatase inhibition to neuroblastoma biology. The high score is a model output and has not been checked against clinical or laboratory findings. It should be treated as a hypothesis to test, not as a supported repurposing opportunity.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
India Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 201544 | Stazonex Tablet | strip of 10 tablets | Not recorded |
| 14122 | Altrol 1mg Tablet | strip of 14 tablets | Not recorded |
| 78860 | Egsure 1mg Tablet | strip of 5 tablets | Not recorded |
| 6826 | Atraz 1mg Tablet | strip of 10 tablets | Not recorded |
| 224544 | Trazocad 1mg Tablet | strip of 10 tablets | Not recorded |
The list shows 5 of the licences compiled for this report and may be partial. All the licences listed are valid single-ingredient products.
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Hormonal therapy (aromatase inhibitor), not a conventional cytotoxic agent |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert warnings and precautions |
| Handling Protection | Please refer to the package insert warnings and precautions |
Safety Considerations
- Disease-related cautions: The data compiled for this report flag myocardial ischemia and coronary artery disease as conditions of concern. These come from relation data, not from label text.
- Drug Interactions: 147 potential interactions were recorded, none with a graded severity level (all “Unknown”). Examples include bupropion, pantoprazole, glimepiride, morphine, metformin, omeprazole, simvastatin, prednisone and acetylsalicylic acid.
Please refer to the package insert for further safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by the model score. No trials or publications address neuroblastoma, and no mechanistic link to aromatase inhibition has been identified. The evidence level is L5.
To proceed, the following is needed:
- A mechanistic rationale connecting aromatase inhibition (or anastrozole specifically) to neuroblastoma biology
- Preclinical studies in neuroblastoma models
- Mechanism of action data for anastrozole
- Package insert warnings and contraindications, and graded severity for the recorded interactions
- A safety review for the paediatric population, since neuroblastoma mainly affects children
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.